EP Wealth Advisors’s NovoCure NVCR Stock Holding History

EP Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$109K	Buy	+10,029	New	+$125K	﹤0.01%	1455
2023 Q3	–	Sell	-5,781	Closed	-$218K	–	767
2023 Q2	$218K	Buy	5,781 +86	+2%	+$5.34K	﹤0.01%	638
2023 Q1	$202K	Sell	5,695 -759	-12%	-$60.7K	﹤0.01%	578
2022 Q4	$473K	Buy	+6,454	New	+$486K	0.01%	388
2022 Q2	–	Sell	-2,551	Closed	-$211K	–	677
2022 Q1	$211K	Buy	+2,551	New	+$188K	﹤0.01%	565
2021 Q4	–	Sell	-2,555	Closed	-$297K	–	558
2021 Q3	$297K	Buy	2,555 +739	+41%	+$112K	0.01%	430
2021 Q2	$403K	Buy	1,816 +54	+3%	+$10.5K	0.01%	380
2021 Q1	$233K	Buy	+1,762	New	+$279K	0.01%	445

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

EP Wealth Advisors's NVCR Position: Q1 2026 in Review

EP Wealth Advisors opened a new position in NovoCure (NVCR) in Q1 2026: 10,029 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #1455 among its holdings. This is a return to the name: EP Wealth Advisors previously reported a position in NVCR as recently as Q2 2023.

EP Wealth Advisors first reported a position in NVCR in Q1 2021 and has held it in 8 quarters since. The position peaked at $473K in Q4 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

EP Wealth Advisors held 10,029 shares of NovoCure worth $109K as of Q1 2026.
NovoCure was a new EP Wealth Advisors position in Q1 2026.
NovoCure made up ﹤0.01% of EP Wealth Advisors's portfolio in Q1 2026, its #1455 holding.
EP Wealth Advisors first reported a position in NovoCure in Q1 2021 and has held it in 8 quarters since.
EP Wealth Advisors's NovoCure position peaked at $473K in Q4 2022.
222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.